Deals channel feed – Endpoints News

Deals channel feed

In search of a post-Tecfidera hit for MS, Biogen follows Sanofi, Roche down the BTK path — and bets $125M cash on a drug out of China

4 years ago

After monthslong lull, Big Pharma should be ready to pounce on M&A as market settles — analysts

4 years ago

Branching out from diabetes? Novo Nordisk shells out the big bucks for Prothena's ATTR amyloidosis pipeline

4 years ago

Kicking the habit, Philip Morris forges $1.5B deal to acquire Vectura in race to build a top inhaled-drug company

4 years ago

AstraZeneca takes a chance on the STING pathway with F-star

4 years ago

J&J, Sid Mukherjee's Vor team up to pair bispecifics with engineered stem cells for blood cancer

4 years ago

Eli Lilly makes modest bet on 'all-in-human' discovery outfit for ALS drugs, deepening bid in precision neurology

4 years ago

A faded penny stock player folds its cards and hands over the keys in reverse merger

4 years ago

European Commission clears AstraZeneca's $39B bid for Alexion and a future in rare diseases. Now there's just a final hurdle

4 years ago

The CRO madness continues as Goldman Sachs-backed buyer group shells out $8.5B for Parexel

4 years ago

Hal Barron's chase for genetic clues leads GlaxoSmithKline back to neuro — and makes new biotech partner $700M richer overnight

4 years ago

The class of molecules behind one of biotech's biggest Alzheimer's failures gets a new lease on life

4 years ago

Merck extends deal to see what else NGM's discovery engine can come up with

4 years ago

Nestlé is betting $525M on a bid to pioneer world's first microbiome drug

4 years ago

Activist Elliott begins its long-awaited attack on CEO Emma Walmsley and a GlaxoSmithKline that has 'lost its way'

4 years ago

Apellis, Beam team up to test base editing against the broad field of complement disorders

4 years ago

Joe Jimenez and Mark Fishman sign up their 5th drug candidate — and they have another big target in their crosshairs

4 years ago

Gilead, Foresite take an unknown pandemic antiviral public in $250M SPAC deal

4 years ago

Can a small band of biopharma players succeed where Eli Lilly failed? They’re taking a shot

4 years ago

Alzheimer's gold rush inspires $565M deal between Chinese pharma powerhouse and little German biotech

4 years ago

On heels of Aduhelm approval, Bristol Myers jumps back into Alzheimer's race

4 years ago

Roche severs ties with 4D Molecular Therapeutics over blindness gene therapy, marking another setback for the field

4 years ago

EQRx and Exscientia, a pair of self-styled disruptors, team up to overturn the drug pricing apple cart

4 years ago

With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline

4 years ago

First page Previous page 74 75 767778 79 80 Next page Last page